GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway

References

• Yang M, Liu S, Zhang C. The related metabolic diseases and treatments of obesity. Healthcare. 2022;10(9):1616. doi:10.3390/healthcare10091616
   Web of Science ®Google Scholar
• Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321–335. doi:10.1159/000521241
   PubMed Web of Science ®Google Scholar
• Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res. 2004;12(6):887–888. doi:10.1038/oby.2004.107
   PubMedGoogle Scholar
• Zhang X, Xie X, Dou Q, et al. Association of sarcopenic obesity with the risk of all-cause mortality among adults over a broad range of different settings: a updated meta-analysis. BMC Geriatr. 2019;19(1):183. doi:10.1186/s12877-019-1195-y
   PubMedGoogle Scholar
• Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017;127(1):43–54. doi:10.1172/JCI88880
   PubMed Web of Science ®Google Scholar
• Lipina C, Hundal HS. Lipid modulation of skeletal muscle mass and function. J Cachexia Sarcopenia Muscle. 2017;8(2):190–201. doi:10.1002/jcsm.12144
   PubMed Web of Science ®Google Scholar
• Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513–537. doi:10.1038/s41574-018-0062-9
   PubMed Web of Science ®Google Scholar
• El Bizri I, Batsis JA. Linking epidemiology and molecular mechanisms in sarcopenic obesity in populations. Proc Nutr Soc. 2020;1–9. doi:10.1017/S0029665120000075
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21. doi:10.1111/dom.13129
   PubMed Web of Science ®Google Scholar
• Kim B, Tsujimoto T, So R, Zhao X, Oh S, Tanaka K. Changes in muscle strength after diet-induced weight reduction in adult men with obesity: a prospective study. Diabetes Metab Syndr Obes. 2017;10:187–194. doi:10.2147/DMSO.S132707
   PubMed Web of Science ®Google Scholar
• Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163–1172. doi:10.1111/j.1463-1326.2009.01158.x
   PubMed Web of Science ®Google Scholar
• Perna S, Guido D, Bologna C, et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016;28(6):1251–1257. doi:10.1007/s40520-015-0525-y
   PubMed Web of Science ®Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. doi:10.1111/dom.12932
   PubMed Web of Science ®Google Scholar
• Ozeki Y, Masaki T, Kamata A, et al. The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a Pilot Study. Medicines. 2022;9(9):47. doi:10.3390/medicines9090047
   Google Scholar
• Milne JC, Denu JM. The sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol. 2008;12(1):11–17. doi:10.1016/j.cbpa.2008.01.019
   PubMed Web of Science ®Google Scholar
• Gurd BJ. Deacetylation of PGC-1α by SIRT1: importance for skeletal muscle function and exercise-induced mitochondrial biogenesis. Appl Physiol Nutr Metab. 2011;36(5):589–597. doi:10.1139/h11-070
   PubMed Web of Science ®Google Scholar
• Lee D, Goldberg AL. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J Biol Chem. 2013;288(42):30515–30526. doi:10.1074/jbc.M113.489716
   PubMed Web of Science ®Google Scholar
• Li Q, Wu J, Huang J, et al. Paeoniflorin ameliorates skeletal muscle atrophy in chronic kidney disease via AMPK/SIRT1/PGC-1α-mediated oxidative stress and mitochondrial dysfunction. Front Pharmacol. 2022;13:859723. doi:10.3389/fphar.2022.859723
   PubMed Web of Science ®Google Scholar
• Xu F, Li Z, Zheng X, et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes. 2014;63(11):3637–3646. doi:10.2337/db14-0263
   PubMed Web of Science ®Google Scholar
• Lee J, Hong SW, Park SE, et al. Exendin-4 attenuates endoplasmic reticulum stress through a SIRT1-dependent mechanism. Cell Stress Chaperones. 2014;19(5):649–656. doi:10.1007/s12192-013-0490-3
   PubMed Web of Science ®Google Scholar
• Jeon JY, Choi SE, Ha ES, et al. GLP‑1 improves palmitate‑induced insulin resistance in human skeletal muscle via SIRT1 activity. Int J Mol Med. 2019;44(3):1161–1171. doi:10.3892/ijmm.2019.4272
   PubMed Web of Science ®Google Scholar
• Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017;35:200–221. doi:10.1016/j.arr.2016.09.008
   PubMed Web of Science ®Google Scholar
• Tomlinson DJ, Erskine RM, Morse CI, Winwood K, Onambélé-Pearson G. The impact of obesity on skeletal muscle strength and structure through adolescence to old age. Biogerontology. 2016;17(3):467–483. doi:10.1007/s10522-015-9626-4
   PubMed Web of Science ®Google Scholar
• Sishi B, Loos B, Ellis B, et al. Diet-induced obesity alters signalling pathways and induces atrophy and apoptosis in skeletal muscle in a prediabetic rat model. Exp Physiol. 2011;96(2):179–193. doi:10.1113/expphysiol.2010.054189
   PubMed Web of Science ®Google Scholar
• Boozer CN, Schoenbach G, Atkinson RL. Dietary fat and adiposity: a dose-response relationship in adult male rats fed isocalorically. Am J Physiol. 1995;268(4 Pt 1):E546–E550. doi:10.1152/ajpendo.1995.268.4.E546
   PubMedGoogle Scholar
• Rothwell NJ, Stock MJ. The development of obesity in animals: the role of dietary factors. Clin Endocrinol Metab. 1984;13(3):437–449. doi:10.1016/s0300-595x(84)80032-8
   PubMedGoogle Scholar
• Levin BE, Dunn-Meynell AA. Defense of body weight depends on dietary composition and palatability in rats with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2002;282(1):R46–R54. doi:10.1152/ajpregu.2002.282.1.R46
   PubMed Web of Science ®Google Scholar
• Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003;100(6):3077–3082. doi:10.1073/pnas.0630588100
   PubMed Web of Science ®Google Scholar
• Ladenheim EE. Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther. 2015;9:1867–1875. doi:10.2147/DDDT.S58459
   PubMed Web of Science ®Google Scholar
• Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223. doi:10.1038/s41573-021-00337-8
   PubMed Web of Science ®Google Scholar
• van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2014;38(6):784–793. doi:10.1038/ijo.2013.162
   PubMed Web of Science ®Google Scholar
• Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–4488. doi:10.1172/JCI75276
   PubMed Web of Science ®Google Scholar
• Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. doi:10.1172/jci.insight.133429
   PubMed Web of Science ®Google Scholar
• Rakipovski G, Rolin B, Nøhr J, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-/- and LDLr-/- mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018;3(6):844–857. doi:10.1016/j.jacbts.2018.09.004
   PubMedGoogle Scholar
• You B, Dun Y, Fu S, et al. The treatment of rhodiola mimics exercise to resist high-fat diet-induced muscle dysfunction via sirtuin1-dependent mechanisms. Front Pharmacol. 2021;12:646489. doi:10.3389/fphar.2021.646489
   PubMed Web of Science ®Google Scholar
• Connolly AM, Keeling RM, Mehta S, Pestronk A, Sanes JR. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord. 2001;11(8):703–712. doi:10.1016/s0960-8966(01)00232-2
   PubMed Web of Science ®Google Scholar
• Rafael JA, Nitta Y, Peters J, Davies KE. Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmdmdx and Dmdmdx3cv dystrophin-deficient mice. Mamm Genome. 2000;11(9):725–728. doi:10.1007/s003350010149
   PubMed Web of Science ®Google Scholar
• Pahor M, Manini T, Cesari M. Sarcopenia: clinical evaluation, biological markers and other evaluation tools. J Nutr Health Aging. 2009;13(8):724–728. doi:10.1007/s12603-009-0204-9
   PubMed Web of Science ®Google Scholar
• Pasetto L, Olivari D, Nardo G, et al. Micro-computed tomography for non-invasive evaluation of muscle atrophy in mouse models of disease. PLoS One. 2018;13(5):e0198089. doi:10.1371/journal.pone.0198089
   PubMed Web of Science ®Google Scholar
• Frontera WR, Ochala J. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int. 2015;96(3):183–195. doi:10.1007/s00223-014-9915-y
   PubMed Web of Science ®Google Scholar
• Lauterbach MAR, Wunderlich FT. Macrophage function in obesity-induced inflammation and insulin resistance. Pflugers Arch. 2017;469(3–4):385–396. doi:10.1007/s00424-017-1955-5
   PubMed Web of Science ®Google Scholar
• Hulver MW, Berggren JR, Cortright RN, et al. Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab. 2003;284(4):E741–E747. doi:10.1152/ajpendo.00514.2002
   PubMed Web of Science ®Google Scholar
• Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 2008;295(6):E1323–E1332. doi:10.1152/ajpendo.90617.2008
   PubMed Web of Science ®Google Scholar
• Ayala JE, Samuel VT, Morton GJ, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010;3(9–10):525–534. doi:10.1242/dmm.006239
   PubMed Web of Science ®Google Scholar
• Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013;280(17):4294–4314. doi:10.1111/febs.12253
   PubMed Web of Science ®Google Scholar
• Maliszewska K, Adamska-Patruno E, Krętowski A. The interplay between muscle mass decline, obesity, and type 2 diabetes. Pol Arch Intern Med. 2019;129(11):809–816. doi:10.20452/pamw.15025
   PubMedGoogle Scholar
• Milan G, Romanello V, Pescatore F, et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat Commun. 2015;6:6670. doi:10.1038/ncomms7670
   PubMed Web of Science ®Google Scholar
• Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117(3):399–412. doi:10.1016/s0092-8674(04)00400-3
   PubMed Web of Science ®Google Scholar
• Knight JD, Kothary R. The myogenic kinome: protein kinases critical to mammalian skeletal myogenesis. Skelet Muscle. 2011;1:29. doi:10.1186/2044-5040-1-29
   PubMed Web of Science ®Google Scholar
• Klip A, McGraw TE, James DE. Thirty sweet years of GLUT4. J Biol Chem. 2019;294(30):11369–11381. doi:10.1074/jbc.REV119.008351
   PubMed Web of Science ®Google Scholar
• Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem. 2005;280(16):16456–16460. doi:10.1074/jbc.M501485200
   PubMed Web of Science ®Google Scholar
• Fujita H, Shimizu K, Nagamori E. Novel method for fabrication of skeletal muscle construct from the C2C12 myoblast cell line using serum-free medium AIM-V. Biotechnol Bioeng. 2009;103(5):1034–1041. doi:10.1002/bit.22318
   PubMed Web of Science ®Google Scholar
• Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473–481. doi:10.1172/JCI10842
   PubMed Web of Science ®Google Scholar
• Guo A, Li K, Tian HC, et al. FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT-1/PGC-α pathway. J Cell Mol Med. 2021;25(7):3585–3600. doi:10.1111/jcmm.16448
   PubMed Web of Science ®Google Scholar
• Cheema U, Yang SY, Mudera V, Goldspink GG, Brown RA. 3-D in vitro model of early skeletal muscle development. Cell Motil Cytoskeleton. 2003;54(3):226–236. doi:10.1002/cm.10095
   PubMed Web of Science ®Google Scholar
• Zou C, Wang Y, Shen Z. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. J Biochem Biophys Methods. 2005;64(3):207–215. doi:10.1016/j.jbbm.2005.08.001
   PubMedGoogle Scholar
• Anwar M, Pradhan R, Dey S, Kumar R. The role of sirtuins in sarcopenia and frailty. Aging Dis. 2023;14(1):25–32. doi:10.14336/AD.2022.0622
   PubMed Web of Science ®Google Scholar
• Cantó C, Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev. 2012;64(1):166–187. doi:10.1124/pr.110.003905
   PubMed Web of Science ®Google Scholar
• Tonkin J, Villarroya F, Puri PL, Vinciguerra M. SIRT1 signaling as potential modulator of skeletal muscle diseases. Curr Opin Pharmacol. 2012;12(3):372–376. doi:10.1016/j.coph.2012.02.010
   PubMed Web of Science ®Google Scholar